Tumor-derived tissue factor aberrantly activates complement and facilitates lung tumor progression via recruitment of myeloid-derived suppressor cells

International Journal of Molecular Sciences

Volumn 18, Issue 1, 2017, Pages

  Han, Xiao ^a   Zha, Haoran ^a   Yang, Fei ^a   Guo, Bo ^a   Zhu, Bo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Complement; Myeloid derived suppressor cells; Tumor derived tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; THROMBOPLASTIN; COMPLEMENT COMPONENT C5A RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE ACTIVATED CELL SORTING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; OPTICAL DENSITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTHROMBIN TIME; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; A-549 CELL LINE; ANIMAL; APOPTOSIS; BLOOD; BLOOD CLOTTING; CELL PROLIFERATION; COMPLEMENT ACTIVATION; DISEASE COURSE; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; NUDE MOUSE; PATHOLOGY;

A549 CELLS; ANIMALS; APOPTOSIS; BLOOD COAGULATION; CELL PROLIFERATION; COMPLEMENT ACTIVATION; DISEASE PROGRESSION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICE, NUDE; MYELOID-DERIVED SUPPRESSOR CELLS; RECEPTOR, ANAPHYLATOXIN C5A; THROMBOPLASTIN;

EID: 85010818144     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18010022     Document Type: Article

References (43)

1. Falanga, A.; Russo, L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie 2012, 32, 115–125.
2. Cocco, E.; Hu, Z.; Richter, C.E.; Bellone, S.; Casagrande, F.; Bellone, M.; Todeschini, P.; Krikun, G.; Silasi, D.A.; Azodi, M., et al. hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br. J. Cancer 2010, 103, 812–819.
3. Hong, H.; Zhang, Y.; Nayak, T.R.; Engle, J.W.; Wong, H.C.; Liu, B.; Barnhart, T.E.; Cai, W. Immuno-pet of tissue factor in pancreatic cancer. J. Nucl. Med. 2012, 53, 1748–1754.
4. Uno, K.; Homma, S.; Satoh, T.; Nakanishi, K.; Abe, D.; Matsumoto, K.; Oki, A.; Tsunoda, H.; Yamaguchi, I.; Nagasawa, T., et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br. J. Cancer 2007, 96, 290–295.
5. Eisenreich, A.; Zakrzewicz, A.; Huber, K.; Thierbach, H.; Pepke, W.; Goldin-Lang, P.; Schultheiss, H.P.; Pries, A.; Rauch, U. Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells. Oncol. Rep. 2013, 30, 462–470.
6. Goldin-Lang, P.; Tran, Q.V.; Fichtner, I.; Eisenreich, A.; Antoniak, S.; Schulze, K.; Coupland, S.E.; Poller, W.; Schultheiss, H.P.; Rauch, U. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol. Rep. 2008, 20, 123–128.
7. Unruh, D.; Sagin, F.; Adam, M.; van Dreden, P.; Woodhams, B.J.; Hart, K.; Lindsell, C.J.; Ahmad, S.A.; Bogdanov, V.Y. Levels of alternatively spliced tissue factor in the plasma of patients with pancreatic cancer may help predict aggressive tumor phenotype. Ann. Surg. Oncol. 2015, 22, 1206–1211.
8. Leppert, U.; Eisenreich, A. The role of tissue factor isoforms in cancer biology. Int. J. Cancer 2015, 137, 497–503.
9. Fang, J.; Gu, L.; Zhu, N.; Tang, H.; Alvarado, C.S.; Zhou, M. Tissue factor/FVIIa activates Bcl-2 and prevents doxorubicin-induced apoptosis in neuroblastoma cells. BMC Cancer 2008, 8, 69.
10. Aberg, M.; Johnell, M.; Wickstrom, M.; Siegbahn, A. Tissue factor/FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor death-associated protein kinase 1 (DAPK1). Thromb. Res. 2011, 127, 141–148.
11. Liu, Y.; Jiang, P.; Capkova, K.; Xue, D.; Ye, L.; Sinha, S.C.; Mackman, N.; Janda, K.D.; Liu, C. Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res. 2011, 71, 6492–6502.
12. Gil-Bernabe, A.M.; Ferjancic, S.; Tlalka, M.; Zhao, L.; Allen, P.D.; Im, J.H.; Watson, K.; Hill, S.A.; Amirkhosravi, A.; Francis, J.L., et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012, 119, 3164–3175.
13. Merle, N.S.; Church, S.E.; Fremeaux-Bacchi, V.; Roumenina, L.T. Complement system part I—Molecular mechanisms of activation and regulation. Front. Immunol. 2015, 6, 262.
14. Heeger, P.S.; Kemper, C. Novel roles of complement in t effector cell regulation. Immunobiology 2012, 217, 216–224.
15. Kunkel, S.L.; Fantone, J.C.; Ward, P.A. Complement mediated inflammatory reactions. Pathobiol. Annu. 1981, 11, 127–154.
16. Markiewski, M.M.; DeAngelis, R.A.; Benencia, F.; Ricklin-Lichtsteiner, S.K.; Koutoulaki, A.; Gerard, C.; Coukos, G.; Lambris, J.D. Modulation of the antitumor immune response by complement. Nat. Immunol. 2008, 9, 1225–1235.
17. Corrales, L.; Ajona, D.; Rafail, S.; Lasarte, J.J.; Riezu-Boj, J.I.; Lambris, J.D.; Rouzaut, A.; Pajares, M.J.; Montuenga, L.M.; Pio, R. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J. Immunol. 2012, 189, 4674–4683.
18. Huber-Lang, M.; Sarma, J.V.; Zetoune, F.S.; Rittirsch, D.; Neff, T.A.; McGuire, S.R.; Lambris, J.D.; Warner, R.L.; Flierl, M.A.; Hoesel, L.M., et al. Generation of C5a in the absence of C3: A new complement activation pathway. Nat. Med. 2006, 12, 682–687.
19. Amara, U.; Flierl, M.A.; Rittirsch, D.; Klos, A.; Chen, H.; Acker, B.; Bruckner, U.B.; Nilsson, B.; Gebhard, F.; Lambris, J.D., et al. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 2010, 185, 5628–5636.
20. Krisinger, M.J.; Goebeler, V.; Lu, Z.; Meixner, S.C.; Myles, T.; Pryzdial, E.L.; Conway, E.M. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 2012, 120, 1717–1725.
21. Bastarache, J.A.; Wang, L.; Geiser, T.; Wang, Z.; Albertine, K.H.; Matthay, M.A.; Ware, L.B. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 2007, 62, 608–616.
22. Toomey, J.R.; Kratzer, K.E.; Lasky, N.M.; Broze, G.J. Effect of tissue factor deficiency on mouse and tumor development. Proc. Natl. Acad. Sci. USA 1997, 94, 6922–6926.
23. Versteeg, H.H.; Schaffner, F.; Kerver, M.; Petersen, H.H.; Ahamed, J.; Felding-Habermann, B.; Takada, Y.; Mueller, B.M.; Ruf, W. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008, 111, 190–199.
24. Kakkar, A.K.; DeRuvo, N.; Chinswangwatanakul, V.; Tebbutt, S.; Williamson, R.C. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995, 346, 1004–1005.
25. Ueno, T.; Toi, M.; Koike, M.; Nakamura, S.; Tominaga, T. Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration. Br. J. Cancer 2000, 83, 164–170.
26. Nitori, N.; Ino, Y.; Nakanishi, Y.; Yamada, T.; Honda, K.; Yanagihara, K.; Kosuge, T.; Kanai, Y.; Kitajima, M.; Hirohashi, S. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2005, 11, 2531–2539.
27. Eisenreich, A.; Bolbrinker, J.; Leppert, U. Tissue factor: A conventional or alternative target in cancer therapy. Clin. Chem. 2016, 62, 563–570.
28. Anand, M.; Brat, D.J. Oncogenic regulation of tissue factor and thrombosis in cancer. Thromb. Res. 2012, 129, 46–49.
29. Eisenreich, A.; Boltzen, U.; Malz, R.; Schultheiss, H.P.; Rauch, U. Overexpression of alternatively spliced tissue factor induces the pro-angiogenic properties of murine cardiomyocytic HL-1 cells. Circ. J. 2011, 75, 1235–1242.
30. Delluc, A.; Rousseau, A.; Delluc, C.; Le Moigne, E.; Le Gal, G.; Mottier, D.; van Dreden, P.; Lacut, K. Venous thromboembolism in patients with pancreatic cancer: Implications of circulating tissue factor. Blood Coagul. Fibrinolysis 2011, 22, 295–300.
31. Zwicker, J.I.; Liebman, H.A.; Neuberg, D.; Lacroix, R.; Bauer, K.A.; Furie, B.C.; Furie, B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer Res. 2009, 15, 6830–6840.
32. Xu, C.; Gui, Q.; Chen, W.; Wu, L.; Sun, W.; Zhang, N.; Xu, Q.; Wang, J.; Fu, X. Small interference RNA targeting tissue factor inhibits human lung adenocarcinoma growth in vitro and in vivo. J. Exp. Clin. Cancer Res. 2011, 30, 63–74.
33. Zhou, H.; Hu, H.; Shi, W.; Ling, S.; Wang, T.; Wang, H. The expression and the functional roles of tissue factor and protease-activated receptor-2 on SW620 cells. Oncol. Rep. 2008, 20, 1069–1076.
34. Ruf, W.; Dorfleutner, A.; Riewald, M. Specificity of coagulation factor signaling. J. Thromb. Haemost. 2003, 1, 1495–1503.
35. Litwin, S.E.; Raya, T.E.; Anderson, P.G.; Daugherty, S.; Goldman, S. Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. J. Clin. Investig. 1990, 86, 481–488.
36. Yu, J.L.; May, L.; Lhotak, V.; Shahrzad, S.; Shirasawa, S.; Weitz, J.I.; Coomber, B.L.; Mackman, N.; Rak, J.W. Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 2005, 105, 1734–1741.
37. Zhang, Y.; Deng, Y.; Luther, T.; Muller, M.; Ziegler, R.; Waldherr, R.; Stern, D.M.; Nawroth, P.P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J. Clin. Investig. 1994, 94, 1320–1327.
38. Yousef, G.M.; Kopolovic, A.D.; Elliott, M.B.; Diamandis, E.P. Genomic overview of serine proteases. Biochem. Biophys. Res. Commun. 2003, 305, 28–36.
39. Veldman, A.; Hoffman, M.; Ehrenforth, S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa. Curr. Med. Chem. 2003, 10, 797–811.
40. Ghebrehiwet, B.; Silverberg, M.; Kaplan, A.P. Activation of the classical pathway of complement by hageman factor fragment. J. Exp. Med. 1981, 153, 665–676.
41. Hakulinen, J.; Meri, S. Complement-mediated killing of microtumors in vitro. Am. J. Pathol. 1998, 153, 845–855.
42. Sayegh, E.T.; Bloch, O.; Parsa, A.T. Complement anaphylatoxins as immune regulators in cancer. Cancer Med. 2014, 3, 747–758.
43. Xiang, T.; Long, H.; He, L.; Han, X.; Lin, K.; Liang, Z.; Zhuo, W.; Xie, R.; Zhu, B. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer. Oncogene 2015, 34, 165–176.